High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala- azar dermal leishmaniasis

Clinical and Experimental Immunology

Volumn 111, Issue 1, 1998, Pages 64-69

  Gasim, S ^a,d   Elhassan, A M ^b   Khalil, E A G ^b   Ismail, A ^a   Kadaru, A M Y ^c   Kharazmi, A ^a   Theander, T G ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c Tropical Diseases Hospital   (Sudan)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dermal; IL 10; Kala azar; Leishmaniasis; Pathogenesis; Post kala azar; Soluble IL 2 receptor; Soluble IL 4 receptor; Visceral

Indexed keywords

INTERLEUKIN 10;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KERATINOCYTE; LEISHMANIA; MALE; MONONUCLEAR CELL; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; SKIN BIOPSY; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; FEMALE; HUMANS; INTERLEUKIN-10; KERATINOCYTES; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; PREDICTIVE VALUE OF TESTS;

EID: 0031930486     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00468.x     Document Type: Article

References (19)

1. Ibrahim ME, Evans DA, Theander TG, El Hassan AM, Kharazmi A. Diversity among Leishmania isolates from the Sudan: isoenzyme homogeneity of L. donovani versus heterogeneity of L. major. Trans Roy Trop Med Hyg 1995; 89:366-9.
2. El Hassan AM, Ghalib HW, Zijlstra EE, ElToum IA, Satti M, Ali MS, Ali HMA. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment. Trans Roy Soc Trop Med Hyg 1992; 86:245-8.
3. + cells in intracellular infections in human: Leishmania as an example. Immunol Today 1996; 17:13-17.
4. Zijlstra EE, El Hassan AM, Ismael A. Endemic kala-azar in Eastern Sudan: post kala-azar dermal leishmaniasis. Am J Trop Med Hyg 1995; 52:299-305.
5. Hviid L, Albeck G, Hansen B, Theander TG, Talbot A. A new portable device for automatic controlled-gradient cryopreservation of blood mononuclear cells. J Immunol Methods 1993; 157:135-42.
6. Gaafar A, Kharazmi A, Ismail A et al. Dichotomy of the T-cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis. Absence or scarcity of Th1 activity is associated with severe infections. Clin Exp Immunol 1995; 100:239-45.
7. Zijlstra EE, El Hassan AM, Ismail A, Ghalib HW. Endemic kala azar in eastern Sudan: a longitudinal study on the incidence of clinical, subclinical infection and post kala-azar dermal leishmaniasis. Am J Trop Med Hyg 1994; 51:826-36.
8. Manson-Bahr PEC. East African kala-azar with special reference to the pathology, prophylaxis and treatment. Trans Roy Soc Trop Med Hyg 1959; 53:123-7.
9. O'Garra A., Murphy K. Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol 1994; 6:458-66.
10. Berg DJ, Leach MW, Kuhn R, Rajewsky K, Muller W, Davidson NJ, Rennick D. Interleukin 10 but not interleukin 4 is a natural suppressor of cutaneous inflammatory responses. J Exp Med 1995; 182:99-108.
11. Becherel PA, Le Goff L, Ktorza S et al. Interleukin 10 inhibits IgE-mediated nitric oxide synthase induction and cytokine synthesis in normal human keratinocytes. Eur J Immunol 1995; 25:2992-5.
12. Cillari E, Vitale G, Arcoleo F et al. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 1995; 7:740-5.
13. Ghalib HW, Piuvezam MR, Sheiky Y et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993; 92:324-9.
14. Karp CL, El Safi SH, Wynn TA et al. In vivo cytokine profiles in patients with kala-azar. J Clin Invest 1993; 91:1644-8.
15. Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, de Sousa A. Potential role for interleukin 10 in the immune suppression associated with kala-azar. J Clin Invest 1993; 92:2626-32.
16. Powrie F, Menon S, Coffman RL. Interleukin-4 and interleukin 10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 1993; 23:2223-9.
17. Josimovic-Alasevic O, Feldmeier H, Zwingenberger K, Harms G, Haln H, Shrisuphanunt M, Diamantstein T. Interleukin 2 receptor in patients with localised and systemic diseases. Clin Exp Immunol 1988; 72:249-54.
18. Vitale G, Reina G, Mansucto S et al. The significance of serum soluble IL-2 receptor as a marker for active visceral leishmaniasis in Sicilian patients. Clin Exp Immunol 1992; 90:219-22.
19. Nobors GS, Farrell JP. Successful chemotherapy in experimental leishmaniasis is influenced by the polarity of T cell response before treatment. J Infect Dis 1996; 173:979-86.